Patents Assigned to Pfizer
  • Corticotropin releasing factor antagonists
    Patent number: 6403599
    Abstract: A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc
    Inventors: Yuhpyng L. Chen, Anthony A. Fossa
  • Processes and intermediates in the synthesis of 5-(3-exo-bicyclo[2.2.1]hept-2-yloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one
    Patent number: 6399776
    Abstract: This invention relates to novel processes for preparing the pharmaceutically active compound 5-(3-[(2S)-exo-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidin-2(1H)-one and its corresponding 2R enantiomer and for preparing certain intermediates used in the synthesis of these compounds. It also relates to novel intermediates used in the synthesis of such pharmaceutically active compounds and to other novel compounds that are related to such intermediates.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 4, 2002
    Assignee: Pfizer INC
    Inventors: Thomas G. LaCour, Charles William Murtiashaw, III
  • Carbazole neuropeptide Y5 antagonists
    Patent number: 6399631
    Abstract: Carbazoles of the formula which are effective in treating conditions associated with neuropeptide Y-5 neurotransmission.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: June 4, 2002
    Assignee: Pfizer Inc.
    Inventors: Richard L. Elliott, David A. Griffith, Marlys Hammond
  • Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
    Patent number: 6399601
    Abstract: This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: June 4, 2002
    Assignee: Pfizer Inc.
    Inventor: Daisy Joe Du Bois
  • Genes encoding branched-chain alpha-ketoacid dehydrogenase complex from Streptomyces avermitilis
    Patent number: 6399324
    Abstract: The present invention relates to novel DNA sequences that encode for the branched-chain alpha-ketoacid dehydrogenase complex of an organism belonging to the genus Streptomyces and to novel polypeptides produced by the expression of such sequences. It also relates to novel methods of enhancing the production of natural avermectin, of producing a Streptomyces avermitilis bkd mutant and of producing novel avermectins through fermentation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 4, 2002
    Assignee: Pfizer Inc.
    Inventors: Claudio D. Denoya, Kim J. Stutzman-Engwall
  • Inclusion complexes of aryl-heterocyclic salts
    Patent number: 6399777
    Abstract: The esylate, mesylate, and tartrate salts of ziprasidone exhibit excellent solubilities in cyclodextrins.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: June 4, 2002
    Assignee: Pfizer Inc.
    Inventors: Yesook Kim, Kevin C. Johnson, Ravi M. Shanker
  • Process for cis-1{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine
    Patent number: 6395911
    Abstract: This invention provides an improved process for cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine which is an intermediate for the preparation of (−)cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol which is useful for the treatment of osteoporosis.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: May 28, 2002
    Assignee: Pfizer Inc.
    Inventor: Charles K. F. Chiu
  • 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
    Patent number: 6395751
    Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: May 28, 2002
    Assignee: Pfizer Inc.
    Inventors: Michael P. DeNinno, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
  • Heterocyclic ring-fused pyrimidine derivatives
    Patent number: 6395733
    Abstract: The present invention relates to heterocyclic ring-fused pyrimidine derivatives of formula (I) or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, wherein Z and Y are as defined in the specification.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: May 28, 2002
    Assignee: Pfizer Inc
    Inventors: Lee Daniel Arnold, Mikel P. Moyer, Susan B. Sobolov-Jaynes
  • Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
    Publication number: 20020061304
    Abstract: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
    Type: Application
    Filed: March 15, 2001
    Publication date: May 23, 2002
    Applicant: PFIZER PRODUCTS INC. & OSI PHARMACEUTICALS, INC.
    Inventors: Penelope Elizabeth Miller, James Dale Moyer
  • Indazole bioisostere replacement of catechol in therapeutically active compounds
    Patent number: 6391872
    Abstract: Therapeutically active compositions of matter and member species thereof are described which comprise indazole-containing compounds, said compounds and their therapeutic activity resulting directly from an indazole-for-catechol bioisostere replacement of a catechol-containing compound having the same therapeutic activity, where non-catechol substituents are the same or homologous before and after said replacement, and wherein said compositions of matter comprise a compound of Formula (I1) or (I2): or a pharmaceutically acceptable salt thereof, wherein in a preferred embodiment RC is hydrogen; RA is cyclohexyl; and RB is ethyl.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: May 21, 2002
    Assignee: Pfizer Inc
    Inventor: Anthony Marfat
  • Oidiodendron strain for the production of terpenoid lactone compounds
    Patent number: 6391616
    Abstract: This invention provides terpenoid lactone compounds, and processes for producing the terpenoid lactone compounds, which comprise cultivating Oidiodedron griseum FERM BP-5778 and then isolating the terpenoid lactone compounds from the fermentation broth. The present invention also provides a pharmaceutical composition comprising the terpenoid lactone compound, which is useful in the treatment of IL-1 and TNF mediated diseases or the like.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: May 21, 2002
    Assignee: Pfizer Inc.
    Inventors: Hiroyuki Nishida, Masaya Ikunaka, Nobuji Yoshikawa, Katsuomi Ichikawa, Nakao Kojima
  • Neospora vaccine
    Publication number: 20020058046
    Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
    Type: Application
    Filed: November 9, 2001
    Publication date: May 16, 2002
    Applicant: Pfizer Inc.
    Inventors: David A. Brake, Manuel Campos
  • Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
    Patent number: 6388092
    Abstract: The present invention relates to compounds of formula 1 and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering compounds of formula 1 to the mammal. The invention also relates to intermediates and methods useful in synthesizing compounds of formula 1.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc
    Inventor: Bingwei V. Yang
  • Method of treating glaucoma and ischemic retinopathy
    Patent number: 6387904
    Abstract: A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: May 14, 2002
    Assignee: Pfizer INC
    Inventor: Harry R. Howard
  • Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
    Patent number: 6387925
    Abstract: Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are Form A and Form B. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in patient receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule and intravenous. A method of making A and B Forms is also disclosed.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc.
    Inventors: George Joseph Quallich, Lewin Theophilus Wint, Peter Robert Rose, Stephen S. Massett
  • Process for preparing cyclic thioamides
    Patent number: 6388127
    Abstract: The present invention relates to a process for preparing a compound of the formula wherein b, Y and R3 are defined as above, useful for preparing novel aralkyl and aralkylidene heterocyclic lactams and imides which are selective agonists and antagonists of serotonin 1 (5-HT1) receptors.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: May 14, 2002
    Assignee: Pfizer INC
    Inventors: George Joseph Quallich, Jeffrey William Raggon, Paul D. Hill
  • Indole derivatives as 5-HT1 agonists
    Patent number: 6387941
    Abstract: Compounds of the formula where W is n is 0, 1, or 2; m is 0, 1, 2, or 3: Y and G are each independently oxygen or sulfur; Z is —O—, —S—, —NH, or —CH2; R1 is hydrogen, C1 to C8 alkyl, substituted C1 to C8 alkyl substituted with one hydroxy, C3 to C8 alkenyl, C3 to C8 alkynyl, aryl, C1 to C3 alkylaryl, C1 to C3 alkylheteroaryl, or —Q—R4; R2 and R2 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkylaryl, or C1 to C3 alkylheteroaryl; R4 is cyano, trifluoromethyl, —COR9, —CO2R9, —CONR9R10, —OR9, —SO2NR(R10, or —S(O)4R8; R9 and R10 are each independently hydrogen, C1 to C8 alkyl, C1 to C3 alkylaryl, aryl, or R9 and R10 may together be taken to form a three- to seven-membered alkyl ring or a three- to seven-membered heteroalkyl ring having 1 heteroatom of O; Q is C1 C3 alkyl; R11 is hydrogen, —Or12, or —NHCOR12; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C3 alkyl-
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc.
    Inventors: John Eugene Macor, Martin James Wythes
  • Isoxazole-sulfonamide endothelin antagonists
    Patent number: 6387915
    Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein. Such compounds are useful in the treatment of conditions mediated by endothelin, in particular, conditions mediated by endothelin ETA.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz
  • Use of CRF antagonists and renin-angiotensin system inhibitors
    Patent number: 6387894
    Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc.
    Inventor: Anthony A. Fossa